RecruitingPhase 2NCT05104983

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Studying Tuberous sclerosis complex

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Darcy Krueger
Principal Investigator
Darcy A Krueger, MD, PhD
Children's Hospital Medical Center, Cincinnati
Intervention
Sirolimus(drug)
Enrollment
64 enrolled
Eligibility
1-6 years · All sexes
Timeline
20212026

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05104983 on ClinicalTrials.gov

Other trials for Tuberous sclerosis complex

Additional recruiting or active studies for the same condition.

See all trials for Tuberous sclerosis complex

← Back to all trials